Pneumonia- VUMC eMERGE v5.1
Identify bacterial pneumonia, similar to that reported with genetic association risk in CD143 and TLR4 A229G in literature.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Hispanic
Rheumatoid Arthritis (RA)
This rheumatoid arthritis (RA) algorithm was created using a machine-learning logistic regression model.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria
Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease that can affect many parts of the body including skin, lungs, brain, heart, kidneys, joints, and blood vessels. SLE presentation can vary significantly between patients. Because of this, it can be challenging to identify a patient as having SLE. Between 300,000 and 2,000,000 people in the US are estimated to have SLE. Determination of an exact number of people affected is challenging as the disease is difficult to identify given the diverse presentations and the length of time it may take for symptoms to appear.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Systemic lupus erythematosus (SLE)
We used Vanderbilt’s Synthetic Derivative (SD), a de-identified version of the EHR, with 2.5 million subjects. We selected all individuals with at least one SLE ICD-9 code (710.0) yielding 5959 individuals. To create a training set, 200 were randomly selected for chart review. A subject was defined as a case if diagnosed with SLE by a rheumatologist, nephrologist, or dermatologist.
Final
Type 1 and type 2 Diabetes Mellitus
This document describes the Stanford University algorithm to extract individuals with diabetes and the type of diabetes from electronic health records (EHRs). There are two main tasks of this phenotype development: 1) to extract patients with diabetes (gestational diabetes is excluded), and 2) to discriminate between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Instead of identifying all diabetes cases, we aim to reduce the number of false positives in our diabetes cohort.
Final
Type 1 Diabetes
Phenotype Algorithm for Type 1 Diabetes – eMERGE Phase-IV Program
Owner Phenotyping Groups:
Final
Type1 or Type 2 Diabetes Mellitus
Phenotyping algorithm for the identification of patients with type 1 or type 2 diabetes mellitus (DM) preoperatively using routinely available clinical data from electronic
health records.
View Phenotyping Groups:
Final
Urinary Incontinence
Description of a weakly supervised machine learning approach for extracting treatment-related side effects (Urinary Incontinence) following prostate cancer therapy from multiple types of free-text clinical narratives, including progress notes, discharge summaries, history and physical notes. Prostatectomy surgery and radiation therapy are our treatments of interest for prostate cancer.
Final
Venous Thromboembolism (VTE)
Recently published GWAS of VTE done by Mayo: http://www.ncbi.nlm.nih.gov/pubmed/22672568
Owner Phenotyping Groups:
View Phenotyping Groups:
Final